{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T20:01:26Z","timestamp":1768593686222,"version":"3.49.0"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,26]]},"DOI":"10.7759\/cureus.97851","type":"journal-article","created":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:17:44Z","timestamp":1764163064000},"source":"Crossref","is-referenced-by-count":1,"title":["Intractable Vomiting in the Setting of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist and Cannabis Usage"],"prefix":"10.7759","author":[{"given":"Peter","family":"DesRochers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linus","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seoyoon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Garrett A","family":"Perchetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roxana","family":"Lazarescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.15620\/cdc\/165794","article-title":"Prevalence of total, diagnosed, and undiagnosed diabetes in adults: United States, August 2021-August 2023","author":"Gwira JA","year":"2024","unstructured":"Gwira JA, Fryar CD, Gu Q. Prevalence of total, diagnosed, and undiagnosed diabetes in adults: United States, August 2021-August 2023. NCHS Data Brief. 2024, 10.15620\/cdc\/165794","journal-title":"NCHS Data Brief"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dci23-0085","article-title":"Economic costs of diabetes in the U.S. in 2022","volume":"47","author":"Parker ED","year":"2024","unstructured":"Parker ED, Lin J, Mahoney T, et al.. Economic costs of diabetes in the U.S. in 2022. Diabetes Care. 2024, 47:26-43. 10.2337\/dci23-0085","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034","article-title":"Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies MJ","year":"2022","unstructured":"Davies MJ, Aroda VR, Collins BS, et al.. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022, 45:2753-86. 10.2337\/dci22-0034","journal-title":"Diabetes Care"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01992-4","article-title":"Tirzepatide: a review in type 2 diabetes","volume":"84","author":"France NL","year":"2024","unstructured":"France NL, Syed YY. Tirzepatide: a review in type 2 diabetes. Drugs. 2024, 84:227-38. 10.1007\/s40265-023-01992-4","journal-title":"Drugs"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-022-05715-4","article-title":"Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis","volume":"65","author":"Karagiannis T","year":"2022","unstructured":"Karagiannis T, Avgerinos I, Liakos A, Del Prato S, Matthews DR, Tsapas A, Bekiari E. Management of type 2 diabetes with the dual GIP\/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia. 2022, 65:1251-61. 10.1007\/s00125-022-05715-4","journal-title":"Diabetologia"},{"key":"ref6","article-title":"Cannabinoid hyperemesis syndrome","volume":"StatPearls Publishing","author":"Cue L","year":"2025","unstructured":"Cue L, Chu F, Cascella M. Cannabinoid hyperemesis syndrome. 2025, StatPearls Publishing:Treasure Island (FL)."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/XCE.0000000000000321","article-title":"GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery","volume":"14","author":"Shankar A","year":"2025","unstructured":"Shankar A, Sharma A, Vinas A, Chilton RJ. GLP-1 receptor agonists and delayed gastric emptying: implications for invasive cardiac interventions and surgery. Cardiovasc Endocrinol Metab. 2025, 14:e00321. 10.1097\/XCE.0000000000000321","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rgmxen.2025.02.002","article-title":"Cannabinoid hyperemesis syndrome: a review","volume":"90","author":"Jim\u00e9nez-Castillo RA","year":"2025","unstructured":"Jim\u00e9nez-Castillo RA, Arumugam S, Remes-Troche JM, Venkatesan T. Cannabinoid hyperemesis syndrome: a review. Rev Gastroenterol Mex (Engl Ed). 2025, 90:214-26. 10.1016\/j.rgmxen.2025.02.002","journal-title":"Rev Gastroenterol Mex (Engl Ed)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo CA","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al.. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30:239-45. 10.1038\/clpt.1981.154","journal-title":"Clin Pharmacol Ther"},{"key":"ref10","article-title":"Current utilization patterns of glucagon-like peptide-1 receptor agonists","author":"Vannabouathong C","year":"2022","unstructured":"Vannabouathong C, Crotty C, Le K, Euric D, Dyrda P. Current utilization patterns of glucagon-like peptide-1 receptor agonists. Canadian Agency for Drugs and Technologies in Health, Ottawa (ON); 2022."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/dc25-0690","article-title":"Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen","volume":"48","author":"Eldor R","year":"2025","unstructured":"Eldor R, Avraham N, Rosenberg O, et al.. Gradual titration of semaglutide results in better treatment adherence and fewer adverse events: a randomized controlled open-label pilot study examining a 16-week flexible titration regimen versus label-recommended 8-week semaglutide titration regimen. Diabetes Care. 2025, 48:1607-11. 10.2337\/dc25-0690","journal-title":"Diabetes Care"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/424202-intractable-vomiting-in-the-setting-of-glucagon-like-peptide-1-glp-1-receptor-agonist-and-cannabis-usage","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T13:17:44Z","timestamp":1764163064000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/424202-intractable-vomiting-in-the-setting-of-glucagon-like-peptide-1-glp-1-receptor-agonist-and-cannabis-usage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":11,"URL":"https:\/\/doi.org\/10.7759\/cureus.97851","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}